Radioimmunotherapy (90Y‐Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-6143|15|7|1976-1981

ISSN： 1600-6135

Source： AMERICAN JOURNAL OF TRANSPLANTATION, Vol.15, Iss.7, 2015-07, pp. : 1976-1981

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 347-353

Karger

Access to resources Recommend Favorite

Yttrium-90 Ibritumomab Tiuxetan-Induced Complete Remission in a Patient with Classical Lymphocyte-Rich Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 31, Iss. 1-2, 2008-01 ,pp. : 49-51

Karger

Access to resources Recommend Favorite

Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment

By  

Acta Haematologica, Vol. 120, Iss. 1, 2008-09 ,pp. : 36-46

Karger

Access to resources Recommend Favorite

Post‐transplant lymphoproliferative disorders with naso‐ and oropharyngeal manifestation

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 11, 2015-11 ,pp. : 1299-1307

John Wiley & Sons Inc

Access to resources Recommend Favorite

Post‐transplant lymphoproliferative disorders with naso‐ and oropharyngeal manifestation

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 934-0874, Iss. 11, 2015-11 ,pp. : 1299-1307

John Wiley & Sons Inc

Access to resources Recommend Favorite